 The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a 4.1 drop over the last five trading days, after another pharmaceutical company - Intellia Therapeutics - announced positive findings from. 